Biofrontera Stock (NASDAQ:BFRI)
Previous Close
$0.76
52W Range
$0.61 - $4.04
50D Avg
$0.97
200D Avg
$1.16
Market Cap
$6.74M
Avg Vol (3M)
$2.73M
Beta
0.51
Div Yield
-
BFRI Company Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKAN | Akanda Corp. |
| EVOK | Evoke Pharma, Inc. |
| ACOR | Acorda Therapeutics, Inc. |
| GHSI | Guardion Health Sciences, Inc. |
| RGC | Regencell Bioscience Holdings Limited |
| IXHL | Incannex Healthcare Limited |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. |
| PTPI | Petros Pharmaceuticals, Inc. |
| HUGE | FSD Pharma Inc. |
| CPIX | Cumberland Pharmaceuticals Inc. |
| PROC | Procaps Group S.A. |
| JUPW | Safety Shot Inc |
| LSDI | Lucy Scientific Discovery Inc. |
| PRFX | PainReform Ltd. |
| AGRX | Agile Therapeutics, Inc. |
| SXTC | China SXT Pharmaceuticals, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |